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Abstract
Background
Studies of vaccine effectiveness (VE) rely on accurate identification of vaccination and
cases of vaccine-preventable disease. In practice, diagnostic tests, clinical case definitions
and vaccination records often present inaccuracies, leading to biased VE estimates. Previ-
ous studies investigated the impact of non-differential disease misclassification on VE
estimation.
Methods
We explored, through simulation, the impact of non-differential and differential disease- and
exposure misclassification when estimating VE using cohort, case-control, test-negative
case-control and case-cohort designs. The impact of misclassification on the estimated VE
is demonstrated for VE studies on childhood seasonal influenza and pertussis vaccination.
We additionally developed a web-application graphically presenting bias for user-selected
parameters.
Results
Depending on the scenario, the misclassification parameters had differing impacts.
Decreased exposure specificity had greatest impact for influenza VE estimation when vacci-
nation coverage was low. Decreased exposure sensitivity had greatest impact for pertussis
VE estimation for which high vaccination coverage is typically achieved. The impact of the
exposure misclassification parameters was found to be more noticeable than that of the dis-
ease misclassification parameters. When misclassification is limited, all study designs per-
form equally. In case of substantial (differential) disease misclassification, the test-negative
design performs worse.
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Conclusions
Misclassification can lead to significant bias in VE estimates and its impact strongly depends
on the scenario. We developed a web-application for assessing the potential (joint) impact
of possibly differential disease- and exposure misclassification that can be modified by
users to their own study scenario. Our results and the simulation tool may be used to guide
better design, conduct and interpretation of future VE studies.
Introduction
Vaccine effectiveness (VE) is defined as a measure of protection among vaccinated persons
attributable to a vaccine administered under field conditions to a given population, which is
different from vaccine efficacy being defined as the effect of vaccination among vaccinated
persons as measured in pre-licensure clinical trials with vaccination allocated under optimal
conditions [1]. Whilst aggregated data may be used for assessment of impact and uptake, indi-
vidual level data are usually required to estimate VE. Such data may be available nationally,
regionally or in health systems which are nationally representative.
When studying VE, it is essential to accurately identify cases of the vaccine preventable dis-
ease and the vaccination status (e.g. defined as 1 dose vs none, 2 doses vs 1 dose, or completely
vs partially vaccinated, depending on the research question of interest). Indeed, assuming mis-
classification is non-differential and independent of other errors, both disease and exposure
misclassifications tend to bias the VE estimates toward the null [2]. Disease and exposure sta-
tuses may reciprocally affect each other’s ascertainment (i.e. differential misclassification) and
lead to biased estimates in either direction [3]. For example, differential disease misclassifica-
tion might arise from differences in healthcare seeking behavior, with subjects more likely to
seek care being more likely vaccinated and also being more likely correctly diagnosed as dis-
eased. Laboratory confirmation is desirable when assessing VE [4]. However, laboratory test
results are not always available or perfectly accurate and, especially in health care database-
based analyses, case definitions often rely on clinical criteria, potentially resulting in disease
misclassification. Different sources of disease misclassification exist and they might be broadly
categorized as under-ascertainment (individuals that do not seek healthcare) and underreport-
ing (individuals that do seek healthcare, but whose health event is not accurately captured due
to various reasons) [5]. Likewise, the vaccination exposure information might be subject to
coding entry error or omissions potentially biasing estimates of VE as well [6].
Concerns regarding disease and exposure misclassifications are particularly relevant when
conducting epidemiological studies using health care databases [7]. Nonetheless, and despite
concerns on data validity, sample representativity and the limited ability to control for con-
founding, there is a strong interest in using large health care databases to study vaccine use
and the outcomes of vaccination by projects such as the Vaccine Safety Datalink [8], Post-
Licensure Rapid Immunization Safety Monitoring programme [9] and ADVANCE (http://
www.advance-vaccines.eu/). Indeed, the size of observational databases allows for the study of
rare events and, as they are embedded within clinical practice, they offer the potential to study
real-world vaccine effects relatively efficiently from both cost and time perspectives.
When conducting VE studies it is important to quantify the potential impact of misclassifi-
cation on the VE estimates in order to assess study feasibility, optimize study design and possi-
bly, the need to correct for misclassification. In earlier work, the impact of non-differential
disease misclassification on influenza VE has been quantified for cohort, case-control and test-
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negative designs based on mathematical derivations [10] and using simulation studies [10, 11].
We extended the simulation study by Orenstein [10] and Jackson [10, 11], to account for both
disease- and exposure misclassification and allow for both differential and non-differential
misclassification. Furthermore, as we show that the impact of misclassification on the esti-
mated VE depends both on the epidemiology of the vaccine preventable disease and the
expected vaccination coverage, we developed a web-application allowing to run simulations
with user-defined parameters. We illustrate the impact of misclassification on VE estimates
using two examples with clearly different disease attack rates and expected vaccination cover-
age; a) childhood pertussis and b) pediatric seasonal influenza VE estimations.
This work was carried out under the auspices of the ‘Accelerated development of vaccine
benefit-risk collaboration in Europe’ (ADVANCE) project, launched in 2013, funded by the
Innovative Medicines Initiative (IMI). The aim of ADVANCE is to help health professionals,
regulatory agencies, public health institutions, vaccine manufacturers, and the general public
make well-informed and timely decisions on benefits and risks of marketed vaccines by estab-
lishing a framework and toolbox to enable rapid delivery of reliable data on vaccine benefits
and risks.
Methods
In this section, we first present analytical derivations illustrating the impact of misclassification
on VE estimates at population level—hence ignoring estimation error—when considering
misclassification in its simplest form, being single source non-differential misclassification.
Although estimation error is ignored, such analytical derivations provide meaningful insights.
However, the derivations become tedious in situations where misclassification is more com-
plex, especially when considering the joint impact of disease and exposure misclassification.
Therefore, we also assess through simulation the impact of differential and non-differential
disease and exposure misclassification when estimating VE using cohort, case-control, test-
negative case-control and case-cohort (screening method) designs. These designs are used to
estimate VE, with the classical cohort and case-control designs being probably the most com-
monly used ones [12]. The test-negative case-control design is popular for estimating VE of
vaccines for influenza and rotavirus [13]. In the test-negative design, the study population are
patients who are seeking medical care for a defined clinical condition (e.g. acute respiratory ill-
ness) and are tested for a specific viral infection (e.g. influenza). Then, patients testing positive
are the cases and patients testing negative are the controls. Finally, the case-cohort or screening
method uses data on the exposure prevalence in cases and compares this to the exposure prev-
alence from an external coverage cohort, from which the cases originate [14].
Notation
First, let πVPD.0 be the unobserved ‘true’ risk of disease due to the pathogen targeted by the vac-
cine (vaccine preventable disease, VPD) in unvaccinated subjects, πOther the corresponding
risk of similar disease due to other pathogens than those targeted by the vaccine, and let γ be
the ‘true’ vaccination coverage. Vaccination affects the VPD risk, with the risk among the vac-
cinated πVPD.1 = (1 − VE)πVPD.0, but does not affect the other disease risk. Furthermore, let p0
be the observed disease prevalence among the subjects indicated as unvaccinated and p1 the
observed prevalence among the subjects indicated as vaccinated. Finally, let SEd be the disease
sensitivity (probability of being indicated as diseased if truly diseased) and SPd the disease
specificity (probability of being indicated as not diseased if truly not diseased) of the case defi-
nition. Similarly let SEe be the exposure sensitivity (probability of being indicated as exposed if
truly exposed) and SPe the exposure specificity (probability of being indicated as unexposed if
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truly unexposed) of the exposure ascertainment definition. In the case of differential misclassi-
fication, the disease misclassification parameters depend on exposure status and vice versa,
yielding four disease misclassification parameters; SEd,E = 0, SEd,E = 1, SPd,E = 0, SPd,E = 1 (with
E = 0 indicating unvaccinated subjects and E = 1 vaccinated subjects) and four exposure mis-
classification parameters; SEe,D = 0, SEe,D = 1, SPe,D = 0, SPe,D = 1 (with D = 0 indicating not dis-
eased subjects and D = 1 diseased subjects).
Impact of misclassification at population-level
Non-differential disease misclassification. Given the simplifying assumptions of no
exposure misclassification and no co-infection between the VPD and the similar disease due
to other pathogens, the observed disease risk among the unvaccinated is the sum of the proba-
bility of having the VPD and being correctly indicated as such (true positive for disease) and
the probability of having the non-VPD and being incorrectly indicated as having the VPD
(false positive for disease) or
p0 ¼ SEd pVPD:0 þ ð1   SPdÞpOther: ð1Þ
Similarly, for the vaccinated, the observed disease risk equals
p1 ¼ SEd pVPD:1 þ ð1   SPdÞpOther; ð2Þ
with πVPD.1 = (1 − VE)πVPD.0.
In line with Orenstein [10] and analogous to the statistical definition of bias, we define the
population-level bias as the difference in VE for a population with and without misclassifica-
tion or
D ¼ 1  
p1
p0
 
  1  
pVPD:1
pVPD:0
 
¼
pVPD:1
pVPD:0
 
SEd pVPD:1 þ ð1   SPdÞpOther
SEd pVPD:0 þ ð1   SPdÞpOther
: ð3Þ
This expression can be rewritten as
D ¼
ðpVPD:1   pVPD:0Þð1   SPdÞpOther
pVPD:0ðSEd pVPD:0 þ ð1   SPdÞpOtherÞ
; ð4Þ
showing that the bias equals zero if the disease specificity equals one, and this irrespective of
the disease sensitivity.
Now, solving (1) for πVPD.0 and (2) for πVPD.1, we have
pVPD:0 ¼ ðp0   ð1   SPdÞpOtherÞ=SEd: ð5Þ
pVPD:1 ¼ ðp1   ð1   SPdÞpOtherÞ=SEd; ð6Þ
based on which, and given accurate estimates of disease misclassification parameters, an esti-
mate of the ‘true’ VE corrected for disease misclassification can be obtained as
VEp ¼ 1  
p1   ð1   SPdÞpOther
p0   ð1   SPdÞpOther
: ð7Þ
Interestingly, the correction equation requires an estimate of disease specificity but not of
disease sensitivity. Obviously, the latter only holds if the disease misclassification is non-differ-
ential by vaccination status.
Non-differential exposure misclassification. Given the simplifying assumption of no
disease misclassification the disease prevalence among subjects indicated as unvaccinated is
Misclassification and vaccine effectiveness
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the sum of the probability of having the VPD and being incorrectly indicated as unvaccinated
(false negative for vaccination), and the probability of having the VPD and being correctly
indicated as unvaccinated (true negative for vaccination) or
p0 ¼ ð1   SEeÞ g pVPD:1 þ SPeð1   gÞpVPD:0; ð8Þ
with true vaccination coverage γ. Similarly, the true positives and false positives for vaccination
determine the disease risk among the subjects indicated as vaccinated or
p1 ¼ SEe g pVPD:1 þ ð1   SPeÞð1   gÞ pVPD:0: ð9Þ
The population-level bias due to exposure misclassification is now defined as
D ¼ 1  
p1
p0
 
  1  
pVPD:1
pVPD:0
 
¼
pVPD:1
pVPD:0
 
SEe g pVPD:1 þ ð1   SPeÞð1   gÞ pVPD:0
ð1   SEeÞ g pVPD:1 þ SPeð1   gÞpVPD:0
: ð10Þ
This expression shows that the impact of sensitivity will be largest when coverage is high
whereas the impact of specificity will be largest when coverage is low.
Solving (8) and (9) for πVPD.0 and for πVPD.1, we obtain
pVPD:0 ¼ ðp0SEe   p1ð1   SEeÞÞ=ðð1   gÞðSEe þ SPe   1ÞÞ; ð11Þ
pVPD:1 ¼ ðp1SPe   p0ð1   SPeÞÞ=ðgðSPe þ SEe   1ÞÞ: ð12Þ
Then, an expression of the ‘true’ VE corrected for exposure misclassification corresponds to
VEp ¼ 1  
1   g
g
 
p1SPe   p0ð1   SPeÞ
p0SEe   p1ð1   SEeÞ
: ð13Þ
This correction equation depends—next to the observed disease risks—on both exposure
sensitivity and specificity as well as on the ‘true’ vaccination coverage.
Simulation tool
Similar to Jackson [11], we simulate populations at risk for two outcomes; the VPD and a com-
parable outcome due to infection with one or more pathogen(s) not targeted by the respective
vaccination. We assume that a number of subjects are vaccinated with coverage γ. Unvacci-
nated subjects could develop the VPD (only once) with a risk equal to πVPD.0 and the health
outcome due to infection with other pathogens (only once) with a risk equal to πother. For vac-
cinated subjects, the risk of developing the VPD is reduced to πVPD.1 = (1 − VE)πVPD.0, whereas
the risk due to other pathogens is unaffected by vaccination. We furthermore assume that the
risks of developing both outcomes are independent. After having allocated the ‘true’ disease-
and exposure status, we randomly allow these events to be misclassified. In particular, for the
disease events, diseased cases are misclassified as not diseased with a probability of 1 − SEd and
not diseased cases are misclassified as diseased with a probability of 1 − SPd. The same holds
for the exposure events, but using the exposure sensitivity SEe and specificity SPe parameters to
simulate misclassification. In the case of differential misclassification, the disease misclassifica-
tion parameters depend on exposure status and vice versa, yielding eight misclassification
parameters in total; four disease misclassification parameters; SEd,E = 0, SEd,E = 1, SPd,E = 0,
SPd,E = 1 and four exposure misclassification parameters; SEe,D = 0, SEe,D = 1, SPe,D = 0, SPe,D = 1.
Then, for a given parameter setting, a large number of simulated populations (k = 1,2,. . .K)
of a predefined population size N are generated. Based on the observed exposure and disease
statuses in each population k, VE is estimated using the cohort, case-control, test-negative
Misclassification and vaccine effectiveness
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case-control and case-coverage designs, using case-cohort sampling as recommended in [10,
11] for the case-control designs (Table 1). Then, these estimates are compared with the true
VE used to generate the simulated populations. The biases are compared graphically.
The simulation model is developed using R 3.3.1[15]. To allow modifying the simulations
for other parameter settings/diseases while maximizing user-friendliness, we have encapsu-
lated the source code of the simulation model in a web application created using the Shiny
package [16]. Through the web application, the user can set all the necessary input parameters
and the output files can be downloaded. The application can be found at the ADVANCE web-
site (http://www.advance-vaccines.eu/) or at http://apps.p-95.com/VEMisclassification/.
Scenarios
General settings. In this paper, we present two specific vaccination scenarios, pediatric
seasonal influenza and childhood pertussis vaccination. For each subsequent simulation sce-
nario, we set K = 1000 and N = 50 000 whereas VE, vaccination coverage and the respective
attack rates depend on the specific scenarios detailed below. We vary one-by-one the disease-
or exposure misclassification from {0.50,0.60,. . .1} while fixing the remaining misclassification
parameters to 1.
Pediatric seasonal influenza. For consistency with Orenstein [10] and Jackson [11], we
assumed a 1-dose VE of 70%, an attack rate (AR) of influenza in the unvaccinated of 15% and
an AR of influenza-like illness not caused by influenza of 30%. The pediatric seasonal influenza
vaccination coverage was assumed to be 10%, in line with the coverage rates reported for the
majority of European countries [17].
Pertussis primary series. We assumed a VE of 80%, derived as a conservative value from
a Cochrane systematic review of vaccine efficacy estimates obtained in random clinical trials,
which found the efficacy of acellular pertussis vaccines in pediatric primary series to range
between 71% and 85% for a follow-up period ranging from 17 to 22 months after vaccination
Table 1. Estimation of vaccine effectiveness (VE) for the cohort, case-control, test- negative case-control and case-coverage (screening method) design.
Cohort Case-control Test-negative case-control Screening method
For each
simulated
population
We calculate the VPD risk in
the vaccinated vs in the
unvaccinated.
We identify cases of VPD and sample
controls from the full population at
risk (case-cohort sampling); and for
these two groups compare the odds of
exposure as an odds ratio. We used
case-cohort sampling as it was
recommended in [10].
Here, the cases are the outcome events
due to the VPD pathogen (test-
positives) and the controls are the
outcome events due to other
pathogens (test-negatives).
We use only the exposure statuses of the
observed cases and compare the odds of
exposure in these cases with the odds of
exposure in the external coverage cohort.
Estimate
VE as
cVECo ¼ 1   cRRCo
¼ 1  
bpv
bpu
;
with cRRCo the estimated
ratio of the VPD risk in the
vaccinated vs. unvaccinated;
and estimated risks bpv and
bpu based on observed
proportions of VPD in the
vaccinated and unvaccinated
respectively.
cVE CC ¼ 1   cORCC
¼ 1  
bpd=ð1   bpd Þ
bpn=ð1   bpn Þ
;
with cORCC the estimated ratio of odds
of exposure in cases vs. controls,
which is equivalent to the odds of
VPD in the vaccinated versus
unvaccinated; and bpd and bpn being
the observed proportions of exposure
in the cases and controls respectively.
cVE TN ¼ 1   cORTN
¼ 1  
cptp=ð1   cptp Þ
cptn=ð1   cptn Þ
;
with cORTN the estimated ratio of the
odds of exposure in the cases versus
controls; cptp and cptn observed
proportions of exposure in test-
postitive and test-negative individuals
respectively.
cVE SCREEN ¼ 1   cORSCREEN
¼ 1  
bpd=ð1   bpd Þ
bX=ð1   bXÞ
;
with cORSCREEN being the estimated ratio
of the odds of exposure in the cases vs
the odds of exposure in the external
coverage cohort; bpd is as defined for the
case-control design and bX an estimate of
the vaccine coverage for the external
coverage cohort. For the simulation
model, bX is estimated as the proportion
of individuals with observed exposures,
assuming same levels of misclassification
in the external coverage cohort as in the
cases.
https://doi.org/10.1371/journal.pone.0199180.t001
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[18]. We furthermore assumed that the AR of pertussis in the unvaccinated was 15% [19] and
the AR of the non-vaccine preventable pathogens was 10.5% [20]. For the vaccination cover-
age, we assumed a value of 95%, which reflects a coverage rate commonly reported for the
pediatric primary series in high-income countries[21].
Results
Pediatric seasonal influenza
In the seasonal influenza scenario and assuming non-differential misclassification (Fig 1, left),
the exposure specificity had the largest impact when fixing the remaining parameters to 1
followed by disease specificity and this across all designs. Indeed, the VE was most strongly
underestimated when lowering the exposure specificity from 1 to 0.5. The underestimation in
VE was still pronounced but less when lowering the disease specificity. Lowering the exposure
sensitivity had a negligible impact on the VE whereas lowering the disease sensitivity had no
impact when the remaining parameters were fixed to 1.
In case of differential exposure misclassification (Fig 1, middle), the bias could go in either
direction, with the estimated VE showing very large deviations from the true VE. Across all
designs, the exposure specificity for the diseased had the strongest impact among all four expo-
sure misclassification parameters when fixing the remaining parameters to 1 and biases the VE
estimates downwards. Also the exposure sensitivity for the undiseased yields a downwards
bias. Lowering the exposure sensitivity for the diseased and the exposure specificity for the
undiseased both show a slightly upwards bias.
In case of differential disease misclassification (Fig 1, right), the bias could go in either
direction as well. Across all designs, the disease specificity for the exposed had the largest
(downwards biasing) impact among the four disease misclassification parameters when fixing
the remaining parameters to 1 followed by the disease sensitivity in the unexposed. The disease
sensitivity for the exposed and the disease specificity for the unexposed are both associated
with a slightly upwards bias. The test negative design performs worse than the other designs,
particularly for low levels of disease specificity in the exposed.
Pertussis primary series
In the pertussis scenario and assuming non-differential misclassification (Fig 2, left), the expo-
sure sensitivity had the largest impact when fixing the remaining parameters to 1 followed by
disease specificity. In case of differential exposure misclassification (Fig 2, middle), the expo-
sure sensitivity for the un-diseased had the strongest impact among all four exposure misclassi-
fication parameters and biased the VE estimates downwards. Finally, in case of differential
disease misclassification (Fig 2, right), the disease specificity for the exposed had the largest
impact among the four disease misclassification parameters. The impact of the misclassifica-
tion parameters was comparable across designs. As with pediatric influenza, the bias due to
differential misclassification could go in either direction and lead to very large deviations from
the true VE. Again, misclassification more strongly affects VE estimates from test-negative
designs.
Discussion
The development of the simulation tool has presented an opportunity to explore the inter-
play of disease- and exposure misclassification in VE estimations from different study
designs. In this study, we explored the single impact of non-differential and differential
disease- and exposure misclassification on childhood seasonal influenza and pertussis VE
Misclassification and vaccine effectiveness
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estimation. Depending on the scenario, the misclassification parameters had differing
impacts. Decreased exposure specificity (poorer identification of non-vaccinees) had great-
est impact for influenza VE estimation. Conversely decreased exposure sensitivity (poorer
identification of vaccinees) had greatest impact for Pertussis VE estimation. These different
impacts correspond to the respectively low and high vaccine coverage in the two scenarios,
which is also supported by the analytical derivation (10) in Section 2.2. Similar observations
were made regarding the impact of the exposure prevalence on the predictive values of the
exposure assessment. Indeed, in low prevalence settings, the exposure specificity has the
Fig 1. Influenza scenario: Vaccine effectiveness by design for varying levels of exposure- and disease misclassification while fixing the
remaining parameters to 1. The dashed horizontal lines indicate the true VE used to simulate the data.
https://doi.org/10.1371/journal.pone.0199180.g001
Misclassification and vaccine effectiveness
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greatest impact with the lower the specificity the lower the positive predictive value. Con-
versely, in high prevalence settings, the exposure sensitivity has the greatest impact with the
lower the sensitivity the lower the negative predictive value. Finally, it is interesting to note
that, for the influenza and pertussis scenarios investigated, we found exposure misclassifica-
tion to have a larger impact compared to disease misclassification whereas previous research
focused on disease misclassification only.
The impact of the misclassification parameters was found to be more noticeable than that
of the different study designs, with the different study designs performing similarly when
Fig 2. Pertussis scenario: Vaccine effectiveness by design for varying levels of exposure- and disease misclassification while fixing the
remaining parameters to 1. The dashed horizontal lines indicate the true VE used to simulate the data.
https://doi.org/10.1371/journal.pone.0199180.g002
Misclassification and vaccine effectiveness
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misclassification is limited. Jackson [11] found earlier that VE estimates from test-negative
case-control designs are more biased than those from classical cohort and case-control designs
in case of substantial non-differential disease misclassification. We were able to replicate these
results, and also found that the test-negative design performs particularly worse in case of
substantial differential disease misclassification, with strong downward biases for low levels of
disease specificity in the exposed. The worse performance of the test-negative design can be
intuitively explained by comparing the case-control and test-negative design. In case-control
designs, the false positives originate from the entire population of subjects free of the VPD
with the false positive risk equal to the product of non-VPD risk and 1 minus the disease speci-
ficity. On the other hand, in test-negative designs, the false positives originate from the popula-
tion of test-negatives with the false positive risk equal to 1 minus the disease specificity. Hence,
the relative number of perturbations due to falsely classifying controls as cases is much smaller
for the classical case-control design compared to the test-negative design.
Although the test-negative design is more sensitive to disease misclassification compared to
other designs, its performance remains good when misclassification is limited. Next to misclas-
sification, other sources of bias such a confounding and selection bias should be considered
when selecting an appropriate study design. For instance, observational studies on influenza
VE might be strongly confounded by differences in healthcare seeking behavior between vacci-
nated and unvaccinated persons, therefore the test-negative design might still be the appropri-
ate choice in this case [22].
The dependence of the impact of misclassification on the scenario urged us to develop a
user-friendly simulation tool that can be modified by users to their own study scenario. The
tool allows users to assess the single and joint impact of both differential and non-differential
disease- and exposure misclassification on VE estimates from cohort, case-control, test-nega-
tive case-control and case-coverage studies. The simulation tool can be accessed through
the ADVANCE website (http://www.advance-vaccines.eu/) or using http://apps.p-95.com/
VEMisclassification/.
It is well-known that exposure- and disease misclassification might jeopardize the validity
of VE studies and that such studies require careful design. The simulation tool might help
researchers to anticipate at design stage the magnitude and direction of the bias when estimat-
ing VE based on potentially misclassified data. As such, this tool can guide the selection of the
exposure- and disease definitions that will minimize bias due to misclassification. In addition,
if the potential impact of misclassification is found to be unacceptable, several methods to
adjust estimates for misclassification exist, although they are not yet commonly used in phar-
macoepidemiology [23]. We provided the correction equations for VE estimates in case of
non-differential single source (either exposure or disease) misclassification (Section 2.2).
Other correction methods include amongst others probabilistic bias analyses [24, 25], Bayesian
bias analyses [26–28], modified maximum likelihood methods [29] and imputation-like meth-
ods [30–33]. All these methods require assumptions on or estimates of the disease- and expo-
sure misclassification parameters, which—if deemed required—can be obtained using internal
or external validation studies.
Several limitations or areas of further development are worth considering. The simulation
tool singles out the impact of disease- and exposure misclassification and ignores other sources
of bias. Specifically, it is assumed that there is no confounding and no selection bias. In addi-
tion, the tool does not include dependent misclassification. For binary variables, misclassifica-
tion is dependent when the probability of misclassification of one variable depends on the
correctness of classification on the other variable [34]. Dependent measurement errors might
arise, for example, if data on both exposure and outcome were obtained from medical records
with data paucity for some but not all subjects. Furthermore, the tool assumes binary disease-
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and exposure variables, whereas particularly the exposure variable might be polytomous (no
vaccination, partial or complete vaccination).
The results presented in this paper and the simulation tool may be useful to guide research-
ers to better design, conduct and interpret future VE studies when data are subject to misclas-
sification. We advocate to use such a simulation tool and modify the parameters according to
the study specifics since we have shown that the impact of misclassification strongly depends
on the study scenario.
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